Menu Search
Equities

CARsgen Therapeutics Holdings Ltd

2171:HKG.HS

CARsgen Therapeutics Holdings Ltd

Actions
  • Price (HKD)7.56
  • Today's Change0.85 / 12.67%
  • Shares traded85.30m
  • 1 Year change-30.64%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

  • Revenue in HKD (TTM)6.90m
  • Net income in HKD-756.12m
  • Incorporated--
  • Employees477.00
  • Location
    CARsgen Therapeutics Holdings LtdBuilding 12No.388 Yindu Road, Xuhui DistrictSHANGHAI KY1-1205ChinaCHN
  • Websitehttps://www.carsgen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.